GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BIOGY) » Definitions » Net Issuance of Preferred Stock

BioGaia AB (BioGaia AB) Net Issuance of Preferred Stock : $0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

BioGaia AB's net issuance of preferred for the three months ended in Mar. 2024 was $0.0 Mil. The number is 0, which means that BioGaia AB has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

BioGaia AB's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was $0.0 Mil.

BioGaia AB Net Issuance of Preferred Stock Historical Data

The historical data trend for BioGaia AB's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Net Issuance of Preferred Stock Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioGaia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioGaia AB Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGaia AB (BioGaia AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BIOGY) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
OSTO:SECARE OSTO:PROB OSTO:CRNO B XSAT:EQL OSTO:MOB OSTO:ORX OSTO:ENZY OSTO:VIVE XSAT:DICOT OSTO:ERMA ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ
Traded in Other Exchanges
BGLAF:USA BIOG B:Sweden 0GTN:UK BGLA:Germany
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
Website
https://www.biogaia.se
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.